Publicacións nas que colabora con Eva Poveda López (43)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Elevated plasma levels of IP-10 and MIG are early predictors of loss of control among elite HIV controllers

    Frontiers in Immunology, Vol. 15

  3. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine

2023

  1. IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors

    Frontiers in Immunology, Vol. 14

  2. Interleukin 18 (IL-18) and IL-3 in Extracellular Vesicles: Biomarkers for Durable Elite Control of HIV-1

    Journal of Infectious Diseases

  3. Meningococcal carriage in men who have sex with men presenting at a sexual health unit in Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 42, Núm. 3, pp. 287-296

  4. Plasma Human Immunodeficiency Virus 1 RNA and CD4+T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes with Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study

    Clinical Infectious Diseases

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control

    The Journal of infectious diseases, Vol. 225, Núm. 6, pp. 1040-1049

  3. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  4. Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain

    Frontiers in Public Health, Vol. 10

  5. SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression

    Microorganisms, Vol. 10, Núm. 1

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  3. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2019

  1. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines

    Journal of the International Association of Providers of AIDS Care, Vol. 18

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

  3. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337